Sydney, Australia, June 7, 2024 – LTR Pharma Limited (ASX), a leading pharmaceutical company dedicated to enhancing men's health, is thrilled to announce significant positive outcomes from the pivotal clinical study of SPONTAN® Nasal Spray for the treatment of Erectile Dysfunction (ED).
The recently concluded study revealed that SPONTAN® achieved rapid absorption and faster onset of action compared to traditional oral PDE5 inhibitors like vardenafil, sildenafil, and tadalafil. Notably, SPONTAN's innovative nasal spray technology delivered comparable drug concentrations at just half the dose and in significantly less time.
Key highlights from the study include:
- Rapid Onset: SPONTAN® demonstrated a faster therapeutic effect, achieving peak drug concentrations in an average of 12 minutes—over four times quicker than oral treatments.
- Enhanced Safety Profile: The nasal spray showed better safety and tolerance compared to its oral counterparts, reinforcing its potential as a reliable ED treatment.
- Regulatory Advancements: These promising results will support LTR Pharma in its upcoming regulatory filings across major global markets, including the United States, Australia, Europe, and Asia.
LTR Pharma Chairman, Lee Rodne, said: “The initial results from our pivotal clinical study are encouraging. SPONTAN has the potential to make a significant impact on the global PDE5 inhibitor market, providing men with a more convenient and effective solution for erectile dysfunction (ED). This Study further underscores the rapid onset of action of SPONTAN and represents a significant advancement over existing gold-standard oral therapies, which can take over an hour to take effect. This milestone brings us closer to our mission of enhancing men's health and quality of life.”
About us:
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma’s lead product, SPONTAN, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
Contact details:
Jane Morgan
jm@janemorganmanagement.com.au